Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)

NCT07212751 | Active Not Recruiting

• 1 other identifier: UW20-057
• Study Type: observational
• Target: 22,000
• Locations: 1 country
• Sites: 1

Brief Summary

The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.

Conditions

Determining if the Presence of Adverse Plaque Features Identified From the CT Angiogram Can Help Determining Prognosis and Guide Treatment Options

Keywords

CTCA; CT; Coronary CT; Calcium Score; Plaque; Coronary Artery Disease; CAD; Chest pain; Patients with suspicion of coronary artery disease

Outcome Measures

Primary Outcomes (1)

• Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death

  5 years after CTCA examinations

Secondary Outcomes (1)

• Total plaque, total calcified plaque, total non-calcified plaque, CT-FFR

  5 years after CTCA examinations

Study Arms (1)

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment

Diagnostic Test: CTCA

Interventions

CTCA DIAGNOSTIC_TEST

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment \- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

28000

You may qualify if:

• Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
• If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

You may not qualify if:

• Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine \>250 μmol/L or estimated glomerular filtration rate \<30 mL/min), major allergy to contrast.

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (1)

The University of Hong Kong

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Plaque, Amyloid; Coronary Artery Disease; Chest Pain

Condition Hierarchy (Ancestors)

Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Pain; Neurologic Manifestations; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2025
• First Posted: October 8, 2025
• Study Start: January 29, 2020
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: October 8, 2025

Record last verified: 2025-06

Locations

HK (1)